0KBU Stock Chart & Stats
$11.57
$0.63(5.76%)
At close: 4:00 PM EDT
$11.57
$0.63(5.76%)
Day’s Range― - ―
52-Week Range$3.71 - $18.98
Previous CloseN/A
Volume155.00
Average Volume (3M)7.43K
Market Cap
$856.92M
Enterprise Value$934.76
Total Cash (Recent Filing)$135.32M
Total Debt (Recent Filing)$310.63M
Price to Earnings (P/E)9.1
Beta0.23
Next Earnings
Aug 12, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.30
Shares Outstanding72,375,360
10 Day Avg. Volume2,495
30 Day Avg. Volume7,434
Financial Highlights & Ratios
PEG Ratio3.32
Price to Book (P/B)-9.00
Price to Sales (P/S)0.00
P/FCF Ratio-9.39
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$33.00Price Target Upside185.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.04
Revenue Forecast (FY)$68.00M
Bulls Say, Bears Say
Bulls Say
First-to-market ApprovalRegulatory first‑mover status creates a durable competitive advantage: as the sole approved therapy for TA‑TMA and the first lectin‑pathway inhibitor, YARTEMLEA can establish clinical standard‑of‑care relationships, pricing and hospital pathways that support recurring hospital channel revenues and future label expansions over the next 2–6 months and beyond.
Early Commercial TractionRapid initial uptake across transplant centers and immediate distributor shipments show the commercial model is operational. Early multi‑account ordering and quick logistics indicate scalable supply and adoption, supporting a sustainable revenue ramp and an improving cash flow profile as hospital access and coding progress continue.
Large Non-dilutive FundingA $240M upfront plus milestone structure materially de‑risks near‑term funding need, preserves shareholder equity versus dilutive alternatives, and finances both the YARTEMLEA commercial scale‑up and ongoing pipeline development, extending runway and enabling deliberate R&D and commercialization investments over the coming months.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow of roughly -$95M TTM highlights that core operations still consume cash. Even with early product revenue and upfront proceeds, continued burn forces careful capital allocation, may require further financing if commercial ramp slows, and constrains investments in sales, marketing and trials.
Negative Shareholders' EquityNegative equity signals an impaired capital base and weaker balance sheet flexibility. Even as debt has been reduced, persistent negative equity can limit secured borrowing, increase cost of capital, and reduce strategic optionality for partnerships, acquisitions or large commercial investments during the next several quarters.
Earnings Volatility From ConvertiblesEmbedded derivative remeasurements tied to convertible notes create material quarter‑to‑quarter swings unrelated to operations. With substantial remaining convertible principal and ongoing interest expense, these mark‑to‑market effects and cash interest obligations complicate forecasting, stress reported earnings reliability, and can impair investor confidence over the medium term.
Omeros News
0KBU FAQ
What was Omeros Corp’s price range in the past 12 months?
Omeros Corp lowest share price was $3.71 and its highest was $18.98 in the past 12 months.
What is Omeros Corp’s market cap?
Omeros Corp’s market cap is $856.92M.
When is Omeros Corp’s upcoming earnings report date?
Omeros Corp’s upcoming earnings report date is Aug 12, 2026 which is in 5 days.
How were Omeros Corp’s earnings last quarter?
Currently, no data Available
Is Omeros Corp overvalued?
According to Wall Street analysts Omeros Corp’s price is currently Undervalued.
Does Omeros Corp pay dividends?
Omeros Corp does not currently pay dividends.
What is Omeros Corp’s EPS estimate?
Omeros Corp’s EPS estimate is -0.27.
How many shares outstanding does Omeros Corp have?
Omeros Corp has 72,375,360 shares outstanding.
What happened to Omeros Corp’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Omeros Corp?
Currently, no hedge funds are holding shares in GB:0KBU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Omeros Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$33.00 (185.22% Upside)
$33.00 (185.22% Upside)
Blogger Sentiment
Bullish
GB:0KBU Sentiment 90%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
196.08%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
21.69%
Trailing 12-Months
Company Description
Omeros Corp
Omeros Corporation is a biopharmaceutical firm with commercialized products, actively engaged in the discovery, development, and market introduction of both small-molecule and protein-based therapies, including treatments for rare diseases. The company's therapeutic endeavors primarily focus on inflammatory conditions, illnesses mediated by the complement system, cancers linked to immune system dysregulation, and disorders characterized by addiction or compulsion. Its robust clinical pipeline features several promising candidates. Narsoplimab (also known as OMS721 or MASP-2), a leading asset, has successfully concluded pivotal trials for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA). This drug is also currently undergoing Phase III clinical evaluation for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS), in addition to a Phase II trial investigating its potential for treating COVID-19. Further expanding its clinical portfolio, Omeros is developing PPAR? (OMS405) in Phase II for opioid and nicotine dependence. PDE7 (OMS527) is progressing through Phase I studies for addiction, compulsive disorders, and movement disorders. Additionally, MASP-3 (OMS906) is currently in Phase I trials for paroxysmal nocturnal hemoglobinuria (PNH) and other conditions involving the alternative complement pathway. Beyond its clinical efforts, the company maintains a dynamic preclinical program. This includes small-molecule inhibitors targeting MASP-2, which are being explored for applications in aHUS, IgAN, HSCT-TMA, and age-related macular degeneration. Also in development is a next-generation, longer-acting antibody that targets MASP-2, alongside MASP-3 small-molecule inhibitors designed to address PNH and other alternative pathway disorders. Omeros's preclinical research further encompasses GPR174 inhibitors, as well as Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various oncological indications. The company is also investigating G protein-coupled receptor targets for a broad spectrum of diseases, including immunological, immuno-oncological, metabolic, central nervous system (CNS), cardiovascular, musculoskeletal, and other conditions. Established in 1994, Omeros Corporation is headquartered in Seattle, Washington.
0KBU Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong positive commercial and regulatory momentum driven by the FDA approval and rapid early launch of YARTEMLEA, meaningful non-dilutive capital from the Novo Nordisk transaction, a solid cash position, and multiple pipeline and scientific milestones. Offsetting factors include an adjusted operating loss (excluding noncash items), earnings volatility from mark-to-market adjustments tied to convertible note derivatives, remaining convertible debt, and the early stage of commercial adoption with limited patient-level disclosure. On balance, the highlights around approval, early revenue, cash infusion, reimbursement progress (J-code and potential NTAP), and broad pipeline progress outweigh the near-term financial and volatility headwinds.View all GB:0KBU earnings summaries0KBU Stock 12 Month Forecast
Average Price Target
$33.00
▲(185.22% Upside)
Technical Analysis
Aldeyra Therapeutics
―
Abeona Therapeutics
―
―
Foghorn Therapeutics
―
Neumora Therapeutics, Inc.
―